Previous 10 | Next 10 |
The treatment landscape for kidney cancer has undergone a significant shift in the last decade. Between 2006 and 2009, the U.S. Food and Drug Administration (FDA) approved six drugs for renal cell carcinoma (RCC), the most common form of kidney cancer. A new slate of targeted therapies and immun...
Exelixis (NASDAQ: EXEL) is trading at a bargain price after the market sell-off caused by the COVID-19 pandemic. The biotech stock dropped over 15% from its high of $22.06 in February, now trading around $18. Year to date, the biotechnology stock is up 4.14%, outpacing the Virtus ...
Is now a good time to buy stocks? Given that we have yet to see the full economic impact of the COVID-19 pandemic -- and that equity markets may see even more turbulent days ahead -- some might choose to refrain from purchasing stocks altogether. However, long-term investors may want to take t...
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in a fireside chat as part of the 19 th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 11:20 AM EDT / 8:20 AM PDT. Due to the ongoing COVID-19 pandemic, the c...
The COVID-19 pandemic has done a number on global stock markets this year. Several multibillion-dollar industries, such as airlines, cruise ships, and upscale sit-in restaurants, among many others, are fighting for their very survival right now. Pharmaceutical companies, especially those specia...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
Intro & pipeline Agenus ( AGEN ) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that the...
This year (2020) is quickly going down in the record books as one investors will never forget. Following an 11-year bull market run, we watched as a new bear market instituted itself in less than four weeks, marking the steepest downtrend into bear market territory in history for all three maj...
As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...
That which is common to the greatest number has the least care bestowed upon it, everybody is more inclined to neglect the duty which he expects another to fulfill.” - Aristotle, Politics Markets stabilized somewhat last week after a month of Wuhan coronavirus or Covid-19-trigge...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...